大分割质子束放疗在胰腺癌辅助治疗中的1期研究(PROTON-PANC)
单中心1期试验纳入9例胰腺导管腺癌(PDAC)根治术后患者,在改良FOLFIRINOX(mFFX)化疗第6至7周期之间给予5 Gy×5次大分割质子束放疗(PBT),评价两个剂量水平的安全性;DL2出现1例剂量限制性毒性(持续性3级中性粒细胞减少致mFFX终止),未见局部复发,作者认为需进一步开展2期试验探索。
要点
- 9例胰腺导管腺癌术后患者接受辅助mFFX化疗间期5 Gy×5次大分割PBT,DL1组3例、DL2组6例。
- DL2组发生1例剂量限制性毒性(持续性3级中性粒细胞减少致第7周期后终止mFFX),未见其他剂量限制性毒性。
- 中位随访12.5个月,未见局部复发,5例出现远处复发,2年生存率57%。
核心结论
- 将PBT整合于辅助mFFX化疗中耐受性良好,未观察到局部复发,作者认为这些发现需在2期试验中进一步探索。
研究设计与样本
- 单中心1期试验(NCT03885284),2019年至2022年纳入9例胰腺头部PDAC、接受R0或R1切除并辅助mFFX化疗的患者。
主要发现
- DL1组3例、DL2组6例;DL2组发生1例剂量限制性毒性(持续性3级中性粒细胞减少,导致第7周期后终止mFFX),未见其他剂量限制性毒性。
- 4例完成12个周期mFFX(范围7至12,中位11);无患者出现局部复发。
- 9例中5例复发:肝3例、腹膜1例、骨1例;6例仍存活,其中4例无复发。
- 中位复发时间12个月(95%CI 4至未达到[NR]),中位总生存未达到(95%CI 6至NR;2年生存率57%)。
- 中位年龄66岁(范围52至78),自mFFX开始随访时间12.5个月(范围6.2至37.4个月);无患者接受术前治疗,4例为R1切除,5例淋巴结阳性。
关键数值与推荐
- DL1:28天周期第15至19天给予5 Gy×5次,于第7周期开始前完成。
- DL2:21天周期第8至12天给予5 Gy×5次,于第7周期开始前完成。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 作者在结论中提出这些发现需在2期试验中进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite improvement in systemic therapy, patients with pancreatic ductal adenocarcinoma (PDAC) frequently experience local recurrence. We sought to determine the safety of hypofractionated proton beam radiation therapy (PBT) during adjuvant chemotherapy. METHODS AND MATERIALS: Nine patients were enrolled in a single-institution phase 1 trial (NCT03885284) between 2019 and 2022. Patients had PDAC of the pancreatic head and underwent R0 or R1 resection and adjuvant modified FOLFIRINOX (mFFX) chemotherapy. The primary endpoint was to determine the dosing schedule of adjuvant PBT (5 Gy × 5 fractions) using limited treatment volumes given between cycles 6 and 7 of mFFX. Patients received PBT on days 15 to 19 in a 28-day cycle before starting cycle 7 (dose level 1, DL1) or on days 8 to 12 in a 21-day cycle before starting cycle 7 (DL2). RESULTS: The median patient age was 66 years (range, 52-78), and the follow-up time from mFFX initiation was 12.5 months (range, 6.2-37.4 months). No patients received preoperative therapy. Four had R1 resections and 5 had node-positive disease. Three patients were enrolled on DL1 and 6 patients on DL2. One dose-limiting toxicity (DLT) occurred at DL2 (prolonged grade 3 neutropenia resulting in discontinuation of mFFX after cycle 7). No other DLTs were observed. Four patients completed 12 cycles of mFFX (range, 7-12; median, 11). No patients have had local recurrence. Five of 9 patients had recurrence: 3 in the liver, 1 in the peritoneum, and 1 in the bone. Six patients are still alive, 4 of whom are recurrence-free. The median time to recurrence was 12 months (95% CI, 4 to not reached [NR]), and median overall survival was NR (95% CI, 6 to NR; 2-year survival rate, 57%). CONCLUSIONS: PBT integrated within adjuvant mFFX was well tolerated, and no local recurrence was observed. These findings warrant further exploration in a phase 2 trial.
引用
- Weinberg BA, Wang H, Noel MS, et al. Phase 1 Study of Hypofractionated Proton Beam Radiation Therapy in Adjuvant Pancreatic Cancer (PROTON-PANC). Int J Radiat Oncol Biol Phys. 2023. PMID: 37717786. doi:10.1016/j.ijrobp.2023.09.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。